A Randomized, Placebo-controlled, Double-blind Pilot Study of Single-dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa loa Infection
| Autor: | Michelle Makiya, Amy D. Klion, Roshan Ramanathan, Nicole Holland-Thomas, Jennifer Stoddard, JeanAnne Ware, Jesica A. Herrick, Fanny Legrand, Thomas B. Nutman, Reagan H. Thompson, Shakuntala Rampertaap, Michael P. Fay |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Microbiology (medical) medicine.medical_specialty Pilot Projects Antibodies Monoclonal Humanized Placebo Gastroenterology Diethylcarbamazine Loa Loiasis Double-Blind Method Reslizumab Internal medicine Eosinophilia Eosinophil activation medicine Animals Humans Adverse effect biology business.industry Eosinophil biology.organism_classification Infectious Diseases medicine.anatomical_structure Interleukin-5 medicine.symptom Loa loa business medicine.drug |
| Zdroj: | Clinical Infectious Diseases. 73:e1624-e1631 |
| ISSN: | 1537-6591 1058-4838 |
| DOI: | 10.1093/cid/ciaa1365 |
| Popis: | Background Diethylcarbamazine citrate (DEC) treatment of loiasis is complicated by adverse reactions that are correlated with the number of circulating microfilariae (mf). The cause of these reactions is unknown, but they are accompanied by a dramatic interleukin-5 (IL-5)-dependent increase in eosinophilia and evidence of eosinophil activation. Methods To explore the role of IL-5 driven eosinophilia in post-DEC reactions, 8 adults with confirmed loiasis and Results Baseline characteristics were comparable between the two groups. Single dose reslizumab lowered the AEC by 77% prior to initiation of DEC therapy (vs. 12% in the placebo group, P Conclusions In summary, although reslizumab was able to blunt peripheral eosinophilia post-DEC treatment in subjects with loiasis and had no effect on microfilarial clearance, the reduction in AEC appeared to have been insufficient to prevent post-treatment AEs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|